ArticleBMC microbiology2021
Increased gene expression and copy number of mutated bla
Article in BMC microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Comparative genomics of hypervirulent Klebsiella pneumoniae isolates from Brazil.Archives of microbiology · 2026Article
- Addressing therapeutic options for KPC-3-producing ST307-Antimicrobial agents and chemotherapy · 2026Article
- Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam.BMC genomic data · 2026Article
- Klebsiella pneumoniae in the global AMR: resistance mechanisms and genomic adaptation.World journal of microbiology & biotechnology · 2026Review
- Article
- Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection.The Journal of antimicrobial chemotherapy · 2025Article
- Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants.Journal of global antimicrobial resistance · 2025Article
- Article
- Article
- Article
- A Whole-Genome Sequencing-Based Approach for the Characterization ofMicroorganisms · 2023Article
- Clinical Characteristics and Outcome of Ceftazidime/Avibactam-ResistantOpen forum infectious diseases · 2023Article
- What to Do with the New Antibiotics?Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Multiple Copies of Mobile Tigecycline Resistance Efflux Pump Gene ClusterMicrobiology spectrum · 2022Article
- Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.Antibiotics (Basel, Switzerland) · 2022Review
- Acquisition of resistance to ceftazidime-avibactam during infection treatment inFrontiers in cellular and infection microbiology · 2022Article
- Emergence of Ceftazidime-Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11Infection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla
resultsWe report the mutated bla
conclusionsIncreased gene expression and copy number of mutated bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.